Tuberculosis Clinical Trial
Verified date | July 2015 |
Source | Research Institute for Biological Safety Problems |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The study is a single centre, phase I, double-blind, randomized, placebo-controlled trial that explored the safety and immunogenicity of 2 doses (Day 1 and Day 21) TB/FLU-04L tuberculosis vaccine versus matched placebo in BCG-vaccinated healthy adult subjects aged 18-50 years.
Status | Completed |
Enrollment | 44 |
Est. completion date | February 2015 |
Est. primary completion date | April 2014 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 50 Years |
Eligibility |
Inclusion Criteria: - Healthy BCG-vaccinated male or female adult 18 through 50 years of age at the enrollment visit. - Literate and willing to provide written informed consent. - A signed informed consent. - Capable and willing to complete diary cards and willing to return for all follow-up visits. - For females, willing to take reliable birth control measures throughout the entire period of participation in the study. Exclusion Criteria: - Clinical, radiological (chest X-ray) or laboratory evidence of active or past TB disease. - Current or past administration of anti-TB therapy. - History of contact with TB patients. - Positive QuantiFERON-TB Gold test. - BCG vaccination in less than 6 months prior to study. - Practice of nasal irrigation on a regular basis within the past six months or has engaged in nasal irrigation within two weeks prior to enrollment. - Recent history of frequent nose bleeds (>5 within the past year). - Clinically relevant abnormal paranasal anatomy. - Recent history (within the past month) of rhino or sinus surgery, or surgery for any traumatic injury of the nose. - Current or recent (within two weeks of enrollment) acute respiratory illness with or without fever. - Hypersensitivity after previous administration of any vaccine. - History of chronic alcohol abuse and/or illegal drug use. - Any clinically significant abnormal laboratory finding. - A positive pregnancy test for all women of childbearing potential. - Administration of immunosuppressive drugs or other immune modifying drugs within 4 weeks prior to study enrollment. - Acute or chronic clinically significant pulmonary disease, cardiovascular disease, gastrointestinal disease, liver disease, neurological illness, liver disease, blood disease, skin disorder, endocrine disorder, neurological illness and psychiatric disorder as determined by medical history, physical examination or clinical laboratory screening tests, which in the opinion of the investigator, might interfere with the study objectives. - History of leukemia or any other blood or solid organ cancer. - Seropositive for HIV, hepatitis B surface antigen and/or hepatitis C antibodies. - Receipt of antivirals, antibiotics, immunoglobulins or other blood products within 4 weeks prior to study enrollment or planned receipt of such products during the period of subject participation in the study. - Participation in another clinical trial within the previous three months or planned enrollment in such a trial during the period of this study. - Subjects who are, in the opinion of the investigator, at significantly increased risk of non-cooperation with requirements of the study protocol. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Research Institute for Biological Safety Problems | Ministry of Health, Kazakhstan, Research Institute of Influenza, Russia |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Immediate reactions | Immediate reactions occurring within two hours of administration of any dose | Two hours | |
Primary | Solicited local and systemic reactions | Adverse events commonly associated with intranasal vaccination | Greater than 2 hours after administration of any dose of vaccine or placebo through 7 days following any dose | |
Primary | Unsolicited events and abnormal laboratory findings | Adverse events not associated with intranasal vaccination and abnormal laboratory findings | Greater than 2 hours after administration of any dose of vaccine or placebo through 7 days following any dose | |
Primary | Serious adverse events (SAEs), including abnormal laboratory findings | All SAEs during three weeks after receipt of any dose | Three weeks of receipt of any dose |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05738681 -
Efficacy of N-acetylcysteine to Prevent Anti-tuberculosis Drug-induced Liver Injury: A Randomized Controlled Trial
|
Phase 2/Phase 3 | |
Recruiting |
NCT05526885 -
Tuberculosis Diagnostic Trial of CAD4TB Screening Alone Compared to CAD4TB Screening Combined With a CRP Triage Test, Both Followed by Confirmatory Xpert MTB/RIF Ultra in Communities of Lesotho and South Africa
|
N/A | |
Completed |
NCT04369326 -
Community Initiated Preventive Therapy for TB
|
N/A | |
Recruiting |
NCT04568967 -
TB-CAPT EXULTANT - HIV
|
N/A | |
Completed |
NCT02337270 -
Phase 1 Clinical Trial of the Safety and Immunogenicity of an Adenovirus-based TB Vaccine Administered by Aerosol
|
Phase 1 | |
Not yet recruiting |
NCT06253715 -
Shortened Regimen for Drug-susceptible TB in Children
|
Phase 3 | |
Recruiting |
NCT04271397 -
Immunological Biomarkers in Tuberculosis Management
|
N/A | |
Withdrawn |
NCT03639038 -
Tuberculosis Diagnosis by Flow Cytometry
|
||
Completed |
NCT03199313 -
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Sutezolid
|
Phase 1 | |
Recruiting |
NCT04975178 -
Efficacy, Safety and Immunogenicity Evaluation of MTBVAC in Newborns in Sub-Saharan Africa
|
Phase 3 | |
Completed |
NCT04463680 -
Rifampin and the Contraceptive Implant
|
Phase 4 | |
Completed |
NCT03973970 -
Assessing the Ability of the T-SPOT®.TB Test (IQ)
|
||
Recruiting |
NCT04230395 -
Alcohol Reduction Among People With TB and HIV in India
|
N/A | |
Completed |
NCT04874948 -
Absorption, Elimination and Safety of 14C-labeled Radioactive BTZ-043, a New Compound in TB Treatment
|
Phase 1 | |
Active, not recruiting |
NCT02906007 -
Evaluating the Pharmacokinetics, Safety, and Tolerability of Bedaquiline in Infants, Children, and Adolescents With Multidrug-Resistant Tuberculosis, Living With or Without HIV
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT05917210 -
Peer-led Implementation of TB-HIV Education and Adherence Counseling in Uganda
|
N/A | |
Not yet recruiting |
NCT06017843 -
Impact Evaluation of Use of MATCH AI Predictive Modelling for Identification of Hotspots for TB Active Case Finding
|
N/A | |
Not yet recruiting |
NCT05845112 -
Start Taking Action For TB Diagnosis
|
||
Active, not recruiting |
NCT02715271 -
Study of TB Lesions Obtained in Therapeutical Surgery
|
||
Completed |
NCT02781909 -
Potential Efficacy and Safety of Using Adjunctive Ibuprofen for XDR-TB Tuberculosis
|
Phase 2 |